Cannabis in HIV neuropathic pain: RCT (Abrams)

Introduction and clinical context

The study Cannabis in HIV neuropathic pain: RCT (Abrams) (Neurology · 2007) is part of the scientific research on the use of cannabinoids in hiv neuropathy.

Peripheral neuropathy associated with HIV — and with its treatment — is often refractory neuropathic pain. Classic clinical trials (such as those by Abrams and Ellis) showed that smoked cannabis reduced pain compared with placebo in this population. The findings underpin the interest in cannabis for refractory neuropathic pain, always under medical assessment and in the context of integral care for the person living with HIV.

Understanding what science shows about the use of cannabinoids in hiv neuropathy helps patients and healthcare professionals make safer, well-founded decisions, based on evidence rather than common sense.

Methodology and findings

This clinical trial was conducted in a controlled manner, comparing the treatment with a reference group. RCT (50 patients): smoked cannabis reduced pain by 34% vs 17% with placebo in HIV neuropathy. The blinded, controlled design reduces bias and increases the reliability of the finding. Results from controlled trials like this are especially valuable for guiding therapeutic decisions.

Mechanism of action and safety

In HIV-associated neuropathy, neuropathic pain is modulated by cannabinoids via the endocannabinoid system in the pain pathways, with classic trials demonstrating relief with smoked cannabis. Safety, in the person living with HIV, requires attention to interactions with antiretroviral therapy and to the effect on cognition. Effects such as dizziness and sedation are common, and THC has a dose-dependent psychoactive effect. Use integrates into integral care, with titration and follow-up, considering the immune status and the patient's other medications.

Regulation in Brazil (Anvisa)

In Brazil, access to cannabis products is regulated by Anvisa — mainly through RDC 660/2022 (patient import with a medical prescription) and the new manufacturing and import framework, RDC 1,015/2026. Any therapeutic use must start from an individualized medical assessment and prescription. This content is informative and scientific and does not replace the guidance of a healthcare professional.

This is informative content produced by Brazcann; for the full methodology and detailed results, consult the original publication (Neurology · 2007). Access to cannabis treatments must always occur through the regulated pathway, with a prescription and medical follow-up.

Frequently asked questions

Does cannabis help in HIV neuropathic pain?

Classic trials showed pain reduction vs placebo; use is assessed by a doctor, within integral care.

Are these studies recent?

There are landmark trials from the 2000s (Abrams, Ellis) that underpin the current interest.